Onena Medicines

About

Onena Medicines is a biopharmaceutical company founded in 2019 as a spin-out from Stanford University. Based in Switzerland, the company specializes in AI-optimized antibody medicines that target Dual SMAD Inhibiting Proteins (DSIPs) to treat various conditions, including cancers, rare diseases, anemia, and obesity. The company utilizes a proprietary AI-centric antibody drug discovery platform, featuring a unique computer vision-based system that designs antibodies from scratch. This innovative approach aims to reprogram diseased cells, such as cancer cells, making them more susceptible to cell death by neutralizing DSIPs. Onena is developing a pipeline of first-in-class antibody medicines focused on oncology and other therapeutic areas, addressing significant health challenges.